 LONDON and SAN DIEGO, June 22, 2021 PRNewswire -- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc GSK, with Pfizer Inc. and Shionogi Limited as shareholders, and Halozyme Therapeutics, Inc. Nasdaq: HALO today announced a global collaboration and license agreement that gives exclusive access to Halozymes ENHANZE drug delivery technology, recombinant human hyaluronidase PH20 enzyme rHuPH20, for specific targets used in the treatment and prevention of HIV. Under the terms of the agreement, ViiV Healthcare will make an upfront payment of 40 million to Halozyme for the exclusive license to four HIV small and large molecule targets and is obligated to make potential future payments of up to 175 million in development and commercial milestones per target, subject to achievement of specified development and commercial milestones, including certain specified sales milestones. 